Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced that results from its Phase 3 TRANSCEND trial evaluating setmelanotide in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE